Suzanne Leijen

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

Suzanne Leijen, Sjaak A. Burgers, Dick Pluim et al. · Investigational New Drugs · 2014 · 366 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i>-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke et al. · Journal of Clinical Oncology · 2016 · 343 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2016 · 269 citations · Full text

Medicine, Oncology, Pharmacology +14

AML1/RUNX1 Increases During G1 to S Cell Cycle Progression Independent of Cytokine-dependent Phosphorylation and Induces Cyclin D3 Gene Expression

Florence Bernardin-Fried, Tanawan Kummalue, Suzanne Leijen et al. · Journal of Biological Chemistry · 2004 · 87 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Suzanne Leijen, Mark R. Middleton, Patricia Tresca et al. · Clinical Cancer Research · 2012 · 71 citations

Medicine, Oncology, Pharmacology +17